Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
The Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of acoramidis in the EU based on ...
Business Insider1d
BridgeBio receives positive CHMP opinion for acoramidis for ATTR-CM treatment
Acoramidis is a selective small molecule, orally administered near-complete transthyretin stabilizer. ATTR-CM is a progressive fatal disease that presents as an infiltrative, restrictive ...
FiercePharma19h
EMA backs Merck’s Welireg, Bayer’s ATTR med and Gilead’s liver drug from $4.3B deal
Merck & Co.’s kidney cancer drug Welireg, Bayer and BridgeBio’s transthyretin amyloid cardiomyopathy (ATTR-CM) therapy, and ...
The American Journal of Managed Care7d
Acoramidis Sustains Benefits in Patients With ATTR-CM in Open-Label Extension Study
Scientific Sessions showed that continuous treatment with acoramidis (Attruby; BridgeBio Pharma) significantly reduced the risk of all-cause mortality (ACM) and cardiovascular-related hospitalizations ...
TCTMD1d
Before a Cardiomyopathy Diagnosis, TTR Destabilization Portends Higher Mortality
The findings could potentially enable patients to be identified and treated before symptoms of ATTR-CM emerge.
GEN19d
Bridgebio’s Attruby, to Treat Heart Condition ATTR-CM, Receives FDA Approval
BridgeBio received FDA approval for Attruby (acoramidis), a near complete TTR stabilizer (≥90%), approved to reduce cardiovascular death and cardiovascular-related hospitalization in ATTR-CM ...
Drug acoramidis to treat rare heart disease approved by FDA
The U.S. Food and Drug Administration has approved a drug developed at Stanford Medicine that offers hope to people diagnosed ...
The American Journal of Managed Care19d
FDA Approves Acoramidis for ATTR-CM
Acoramidis is the first FDA-approved treatment for ATTR-CM with near-complete TTR stabilization, reducing cardiovascular death and hospitalization. The phase 3 ATTRibute-CM trial showed acoramidis ...
TCTMD24d
Novel CRISPR-Cas9 Therapy Slows ATTR-CM Progression
CHICAGO, IL—A novel in vivo gene-editing therapy based on CRISPR-Cas9 that targets inactivation of the transthyretin (TTR) gene could slow disease progression in patients with cardiomyopathy caused by ...
Yahoo Finance19d
FDA approves BridgeBio’s Attruby for ATTR-CM treatment
The ATTRibute-CM Phase III trial, which formed the basis for the FDA's approval, enrolled 632 subjects with symptomatic ATTR-CM. Participants were randomised in a 2:1 ratio to receive either ...
Nasdaq21d
BridgeBio announces FDA approved Attruby for ATTR-CM patients
Attruby was designed to mimic a naturally occurring ‘rescue mutation’ of the TTR gene that targets the root cause of ATTR-CM, destabilization of the native TTR tetramer. Through near-complete ...